previous treatment which had consisted of either a diuretic alone , a beta-receptor antagonist alone or these two drugs in combination was discontinued and patients were randomly allocated , in double-blind manner , to a 6-week treatment course of cyclopenthiazide ( navidrex ) or sustained release oxprenolol ( slow-trasicor ) or a fixed combination of these two compounds ( trasidrex ) with the aim of lowering the diastolic pressure to less than 100 mm hg .
C0010581
cyclopenthiazide
C0591849
navidrex